Literature DB >> 27729283

Locally and traditionally used Ligusticum species - A review of their phytochemistry, pharmacology and pharmacokinetics.

Paul Owusu Donkor1, Ying Chen2, Liqin Ding3, Feng Qiu4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Ligusticum species (Umbelliferae) have been widely used in traditional Chinese medicine, Korean folk medicine and Native American medicine for their medicinal and nutritional value. Decoctions of the rhizomes are used in treatment and prophylaxis of migraine, anemia and cardiovascular conditions including stroke.
AIM OF STUDY: This review is intended to fully compile the constituents of locally and traditionally used Ligusticum species, present their bioactivities and highlight potential leads for future drug design, and thus, provide a reference for further research and application of these species. Emphasis is also placed on current trends in the pharmacokinetic studies of the major constituents.
METHODS: The literature discussed is derived from readily accessible papers spanning the early 1990s to the end of 2015. Information was collected from journals, books and online searches (Google Scholar, PubMed, ScienceDirect, SciFinder, Springerlink and CNKI).
RESULTS: The major phytoconstituents, 154 of which are presented in this review, include alkaloids, phthalides and phenolic acids. The crude extracts and isolated constituents have exhibited a wide range of in vitro and in vivo pharmacologic effects, including cardioprotective, antioxidant, anti-inflammatory and neuroprotective activities. The bioactive alkaloid tetramethylpyrazine (TMP) has attracted the most attention for its potent effect on calcium channels, anti-platelet as well as anti-inflammatory effects. Pharmacokinetic studies of major constituents have also been summarized.
CONCLUSION: The pthalides, organic acids and alkaloids of Ligusticum species have emerged as a good source of traditional medicines for the management of cardio- and cerebrovascular conditions, inflammation and neurogenerative disorders. The species discussed in this review have demonstrated wide pharmacological actions and have great potential to yield multipotent drugs if challenges such as poor bioavailability, solubility and toxicological profiles are addressed. Apart from the rhizomes, pharmacological activities of other botanical parts also need to be studied further. Expansion of research to cover other species in the Ligusticum genus would provide more opportunities for the discovery of new bioactive principles.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  1-acetyl-β-carboline (PubChem CID: 638667); 3-Butylidenephthalide (PubChem CID: 62368); Butylidenephthalide (BDPH); Cnidilide (PubChem CID: 160710); Ferulic Acid (PubChem CID: 445858); Ferulic acid (FA); Ligustilide; Ligustilide (PubChem CID: 5319022); Perlolyrine (PubChem CID: 160179); Phthalides; Phytoconstituents; Pregnenolone (PubChem CID: 8955); Senkyunolide H (PubChem CID: 5321251); Senkyunolide I (PubChem CID: 11521428); Tetramethylpyrazine (PubChem CID: 14296); Tetramethylpyrazine (TMP)

Mesh:

Substances:

Year:  2016        PMID: 27729283     DOI: 10.1016/j.jep.2016.10.012

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  17 in total

Review 1.  Prevention and Treatment of Cardiovascular Diseases with Plant Phytochemicals: A Review.

Authors:  Rakesh Kumar Bachheti; Limenew Abate Worku; Yilma Hunde Gonfa; Meseret Zebeaman; D P Pandey; Archana Bachheti
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-04       Impact factor: 2.650

2.  Ligustilide alleviates podocyte injury via suppressing the SIRT1/NF-κB signaling pathways in rats with diabetic nephropathy.

Authors:  Feng Xu; Zi Ye; Shuo Tao; Wangshu Liu; Jianbing Su; Xingxing Fang; Xueqin Wang
Journal:  Ann Transl Med       Date:  2020-09

3.  Pharmacokinetic behaviors of ligustrazine after single- and multiple-dose intravenous Shenxiong glucose injection in rats by high-performance liquid chromatography.

Authors:  Qiong Wang; Huaping Sun; Li Yu; Xianpeng Ma; Baoping Jiang; Changqiong Bi; Zhihua Wang; Qinghong Fan; Yuan Yu; Yueheng Liu; Hong Nie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-04       Impact factor: 3.000

4.  Microneedle-Assisted Percutaneous Delivery of a Tetramethylpyrazine-Loaded Microemulsion.

Authors:  Qiang Zu; Yanyan Yu; Xiaolin Bi; Ren Zhang; Liuqing Di
Journal:  Molecules       Date:  2017-11-21       Impact factor: 4.411

5.  Ligustilide attenuates nitric oxide-induced apoptosis in rat chondrocytes and cartilage degradation via inhibiting JNK and p38 MAPK pathways.

Authors:  Yan Zhou; Jianghua Ming; Yaming Li; Ming Deng; Qing Chen; Yonggang Ma; Zhonghui Chen; Yubiao Zhang; Shiqing Liu
Journal:  J Cell Mol Med       Date:  2019-02-15       Impact factor: 5.310

6.  Ligustrazine Attenuates Myocardial Injury Induced by Coronary Microembolization in Rats by Activating the PI3K/Akt Pathway.

Authors:  Qiang Su; Xiangwei Lv; Ziliang Ye
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

Review 7.  Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids.

Authors:  Chang Hoon Lee
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

8.  Plastomes of eight Ligusticum species: characterization, genome evolution, and phylogenetic relationships.

Authors:  Ting Ren; Zi-Xuan Li; Deng-Feng Xie; Ling-Jian Gui; Chang Peng; Jun Wen; Xing-Jin He
Journal:  BMC Plant Biol       Date:  2020-11-13       Impact factor: 4.215

9.  Tetramethylpyrazine Attenuates the Endotheliotoxicity and the Mitochondrial Dysfunction by Doxorubicin via 14-3-3γ/Bcl-2.

Authors:  Bin Yang; Hongwei Li; Yang Qiao; Qing Zhou; Shuping Chen; Dong Yin; Huan He; Ming He
Journal:  Oxid Med Cell Longev       Date:  2019-12-03       Impact factor: 6.543

10.  Z-Ligustilide Ameliorates Diabetic Rat Retinal Dysfunction Through Anti-Apoptosis and an Antioxidation Pathway.

Authors:  Bing Yang; Guobin Ma; Yang Liu
Journal:  Med Sci Monit       Date:  2020-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.